Why Are Valneva's Shares Trading Higher Monday Premarket?

Loading...
Loading...
  • Valneva SE's VALN COVID-19 vaccine elicits a robust immune response with far fewer side effects than the Oxford/AstraZeneca plc's AZN jab, according to Phase 3 trial results.
  • Valneva said its latest trial, Cov-Compare, included around 4,000 participants aged 18 and older across 26 trial sites.
  • Related: Valneva Shares Plunge As UK Terminates COVID-19 Vaccine Contract: What You Need To Know.
  • Dubbed VLA2001, the vaccine candidate demonstrated superiority against AZD1222 in terms of geometric mean titer for neutralization antibodies and non-inferiority in terms of seroconversion rates in adults aged 30 years and older.
  • The occurrence of COVID-19 cases (exploratory endpoint) was similar between treatment groups. 
  • Valneva said it was preparing for trials in children aged 5 to 12 and a Valneva-sponsored trial to evaluate VLA2001's performance for those needing a vaccine booster shot.
  • Valneva has been expanding the trials of its VLA2001 COVID-19 vaccine candidate and remains in talks with the European Commission over a potential contract.
  • VLA2001 consists of inactivated whole virus particles of SARS-CoV-2, in combination with two adjuvants, alum and Dynavax Technologies Corporation's DVAX CpG 1018.
  • Related: Valneva Continues To Expand COVID-19 Vaccine Candidate Trials.
  • Price Action: VALN stock is up 36.8% at $38.38, and DVAX stock is up 6.85% at $18.1 during the premarket session on Monday's last check.
  • Photo by torstensimon from Pixabay
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsHealth CareSmall CapMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 VaccinePhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...